A detailed history of Two Sigma Investments, LP transactions in Nkarta, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 326,984 shares of NKTX stock, worth $882,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares
326,984
Previous 441,667 25.97%
Holding current value
$882,856
Previous $2.61 Million 43.41%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.52 - $8.0 $518,367 - $917,464
-114,683 Reduced 25.97%
326,984 $1.48 Million
Q2 2024

Aug 14, 2024

BUY
$5.27 - $10.82 $1.02 Million - $2.09 Million
193,520 Added 77.99%
441,667 $2.61 Million
Q1 2024

May 15, 2024

BUY
$5.59 - $15.71 $604,849 - $1.7 Million
108,202 Added 77.32%
248,147 $2.68 Million
Q4 2023

Feb 14, 2024

BUY
$1.31 - $6.6 $183,327 - $923,637
139,945 New
139,945 $923,000
Q2 2023

Aug 14, 2023

SELL
$2.19 - $5.17 $45,849 - $108,239
-20,936 Reduced 16.07%
109,343 $239,000
Q1 2023

May 15, 2023

SELL
$3.37 - $6.3 $276,286 - $516,499
-81,984 Reduced 38.62%
130,279 $462,000
Q4 2022

Feb 14, 2023

BUY
$5.14 - $14.35 $223,245 - $623,263
43,433 Added 25.73%
212,263 $1.27 Million
Q3 2022

Nov 14, 2022

SELL
$12.27 - $18.39 $2.48 Million - $3.72 Million
-202,050 Reduced 54.48%
168,830 $2.22 Million
Q2 2022

Aug 15, 2022

BUY
$7.77 - $19.44 $2.64 Million - $6.6 Million
339,478 Added 1081.07%
370,880 $4.57 Million
Q1 2022

May 16, 2022

SELL
$8.66 - $14.99 $847,632 - $1.47 Million
-97,879 Reduced 75.71%
31,402 $357,000
Q4 2021

Feb 14, 2022

BUY
$12.79 - $26.88 $1.54 Million - $3.24 Million
120,700 Added 1406.6%
129,281 $1.98 Million
Q3 2021

Nov 15, 2021

BUY
$26.67 - $38.76 $228,855 - $332,599
8,581 New
8,581 $239,000

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $131M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.